Commited to Sustainable ExcellenceWed, 09/05/2018 - 10:15
Q: How is DSM Sinochem Pharmaceuticals’ (DSP) cardiovascular and anti-fungal divisions positioned for the medium term?
A: All of DSP’s statins are manufactured in our state-ofthe-art facility in India using a patented partially enzymatic technology that remains unique in the world. As part of our growth plans, we have increased our Atorvastatin sales both via organic market growth as well as with new customers. Following the recent successful introduction of Atorvastatin, we are now also rapidly increasing our presence in Rosuvastatin. The anti-fungals market is stable and we continue with our finished dose formulations in regulated markets.
Q: The Sustainability Report from 2016 shows DSP achieved over 200 marketing authorizations by the end of the year. What are the main milestones for 2018?
A: In 2016 and 2017 it was a great milestone to create such a large portfolio of market authorizations (MA) for European markets. Currently, we are making progress to license these MAs and develop our business in regulated markets. At this time, we do not have any plans to develop these MAs for Mexico.
Q: How does DSP’s environmental and sustainability approach differ from the traditional approach in manufacturing APIs and drug products?
A: Our philosophy behind the sustainable production of antibiotics is quite straight-forward. DSP strives to apply unique technologies that simplify the manufacturing process. The production of our PureActives line has reduced our carbon footprint by 64 percent. Beyond cleaner and simpler manufacturing, DSP is very much involved in controlling the anti-microbial activity levels of our waste streams. This is a global issue that in recent years has received a lot of attention from health and environmental legislators. DSP is at the forefront trying to establish industry guidelines that help protect the efficacy of our current antibiotics.
Q: What message would DSP send to other companies about the impact of implementing a sustainability strategy?
A: DSP has taken on a high-profile campaigning role in the fight against AMR by calling on both the industry and the supply chain to act responsibly in buying, using or selling antibiotics. All pharmaceutical companies should improve monitoring of API emissions in their manufacturing facilities. They need to also support the installations of proper waste-processing facilities onsite to reduce or eliminate API discharge. These efforts should be based on voluntary, transparent and auditable commitments, with a globally consistent quality mark.
Q: Bain Capital Private Equity will acquire DSP. What benefits are you expecting from DSP’s acquisition?
A: Subsequent to approval by the relevant legal and regulatory authorities, DSM Sinochem Pharmaceuticals will be owned by Bain Capital Private Equity. Under this new ownership structure we look forward to a bright new era in which we will be supported by Bain Capital. With their financial, advisory and operational capabilities, combined with their extensive knowledge in the healthcare space, Bain Capital will be able to assist us in achieving our vision. Together with Bain Capital, we are a global leader in highquality APIs and drug products. We remain committed to our core values: quality, reliability and sustainability. As a part of this, we promote responsible manufacturing of antibiotics.
Q: What are the company’s main objectives for Mexico in 2018?
A: DSP is committed to the anti-infective and statins market, as well as the Mexican API industry in general. We believe that Mexico is an excellent location to manufacture high-quality APIs for local markets as well as for larger international markets. In recent years, we have continuously been able to grow our production in Mexico with increased sales all over the world. Our unique and high-quality APIs are approved by relevant regulatory bodies like COFEPRIS, FDA and ANVISA.